Novogen Limited (NASDAQ:KZIA) Stock Has Consensus Price Target of $28.80 According to Analysts

Novogen Limited (NASDAQ:KZIA) has been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $28.80.

KZIA has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Novogen in a report on Thursday, September 10th. Canaccord Genuity Group started coverage on shares of Novogen in a research note on Thursday, August 13th. They set a “buy” rating and a $29.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Friday, July 17th.

Novogen Price Performance

Shares of KZIA opened at $8.04 on Wednesday. Novogen has a one year low of $4.86 and a one year high of $17.40. The stock’s fifty day moving average is $11.64 and its 200-day moving average is $11.99.

About Novogen

Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.